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Abstract: Rosette nanotubes (RNTs) are novel, self-assembled, biomimetic, synthetic drug 
delivery materials suitable for numerous medical applications. Because of their amphiphilic 
character and hollow architecture, RNTs can be used to encapsulate and deliver hydrophobic 
drugs otherwise difficult to deliver in biological systems. Another advantage of using RNTs 
for drug delivery is their biocompatibility, low cytotoxicity, and their ability to engender a 
favorable, biologically-inspired environment for cell adhesion and growth. In this study, a 
method to incorporate dexamethasone (DEX, an inflammatory and a bone growth promoting 
steroid) into RNTs was developed. The drug-loaded RNTs were characterized using diffusion 
ordered nuclear magnetic resonance spectroscopy (DOSY NMR) and UV-Vis spectroscopy. 
Results showed for the first time that DEX can be easily and quickly encapsulated into RNTs 
and released to promote osteoblast (bone-forming cell) functions over long periods of time. As 
a result, RNTs are presented as a novel material for the targeted delivery of hydrophobic drugs 
otherwise difficult to deliver.
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Introduction
Since the first hip replacement surgery in 1923, orthopedic implants have been routinely 
inserted, increasing the quality of life for millions of people.1 A variety of materials 
have been investigated as bone replacements, such as conventional titanium and its 
alloys, micron grain sized ceramics (eg, hydroxylapatite or HA) and nanostructured 
hydrogels (eg, poly-lactic-co-glycolic acid or PLGA).2–5 However, current conventional 
implants suffer from limited lifetimes, often failing before the end of a patient’s natural 
life expectancy.6,7 For example, today’s orthopedic implants usually have insufficient 
initial bone growth on their surface and/or poor maintenance of healthy juxtaposed 
bone over long periods of time. Such problems caused by poor osteointegration of 
the implanted device can lead to bone loss, implant loosening, and ultimately implant 
failure. For example, from October 2005 to December 2006, the number of total hip 
replacement revisions performed in the US reached 51,345 as a result of instability/
dislocation, mechanical loosening and osteolysis.8
To enhance the integration of orthopedic implants with bone forming cells (osteo-
blasts) and surrounding bone, implants with nanostructured surfaces have received 
a tremendous amount of recent attention.9,10 An important member of this class 
of nanomaterials are the rosette nanotubes (RNTs, Figure 1).11–13 RNTs are novel, 
biomimetic, self-assembled, supramolecular structures, whose basic building blocks 
feature the hydrogen bonding arrays of guanine (G) and cytosine (C) DNA bases. International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Figure 1 schematic illustration of the hierarchical self-assembly of rNTs with a lysine side chain. The single unit of K1 (g∧C motif conjugated to a lysine amino acid) 
self-assembles into a rosette ring (lower left), which stacks up to form a stable rNT (right), referred to as K1 in this report.
Abbreviation: rNT, rosette nanontubes.
RNTs are   produced synthetically13 and are assembled under 
physiological conditions. They have been shown to have low 
toxicity14,15 (in vitro and in vivo) and have been shown to have 
anti-cancer properties when functionalized with cell adhesive 
peptides such as arginine-glycine-aspartic acid-serine-lysine 
(RGDSK).16
A heteroaromatic bicyclic base functionalized with 
L-lysine (K–G∧C, Figure 1) undergoes a hierarchical 
self-assembly process under physiological conditions 
to form a six-membered supermacrocycle maintained 
by 18 hydrogen bonds. Because of electrostatic forces, 
base stacking interactions and hydrophobic effects, the 
rosettes form a stable stack with an 11 Å open chan-
nel. L-lysine was chosen to impart chirality, stability, 
biocompatibility, and water solubility. Thus, each of the 
RNT building blocks has a lysine chain, and the resulting 
RNTs (referred to as K1) are covered with lysine amino 
acids (Figure 1). The biomimetic, nanostructured nature 
of RNTs provide a favorable environment for cell adhe-
sion and growth.11,12,17,18
Due to their synthetic accessibility, RNTs have unique 
advantages for drug delivery applications because: a) 
they can be chemically conjugated with bioactive pep-
tides such as RGDSK–RNT (RNTs functionalized with 
Arg-Gly-Asp-Ser-Lys) to improve osteoblast functions on 
hydrogels18 and b) they can be loaded with drugs via hydro-
phobic or   stacking interactions.19
As a first step toward the application of RNTs as novel 
drug delivery devices for orthopedic applications, we investi-
gated the incorporation of dexamethasone (DEX) into RNTs 
and characterized the drug-loaded RNTs by diffusion ordered 
nuclear magnetic resonance spectroscopy (DOSY NMR), 
atomic force microscopy (AFM), and UV–Vis spectroscopy. 
DEX is known to enhance osteoconductivity and is widely 
used in bone tissue engineering.20–22 However, this drug 
interferes with the differentiation of bone marrow-derived 
stem cells into muscle, fat, cartilage and other tissue-forming 
cells.23 Therefore, it is important to deliver DEX to the desired 
site of new bone growth to ensure maximum therapeutic 
activity and specificity.19
Results of this study showed that DEX was indeed 
incorporated into RNTs by simply allowing RNTs to self-
assemble in solution in the presence of DEX. Subsequent 
cell studies demonstrated that DEX was released from the 
RNTs for up to 9 days and had a positive impact on osteo-
blast functions compared to DEX added to cell culture media 
alone. This study thus presents a novel drug delivery system 
where not only is the delivery device itself bioactive, but 
it can also deliver a variety of drugs for various medical 
applications.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Materials and methods
Preparation of rNTs
The self-assembling K–G∧C modules were synthesized 
according to a previously reported strategy.13 They were 
then assembled into RNTs in distilled water (dH2O) to a final 
concentration of 100 µg/mL.
1h and DOsY NMr studies
To test the ability of K1 to deliver hydrophobic drugs, 
4.07 mg of K–G∧C were dissolved in deuterated methanol 
(CD3OD, 1 mL) and aged for 1 day at room temperature. Tert-
butanol (t-BuOH, 1.3 µL, [Sigma, St Louis, MO] $99.5% 
anhydrous) was added as a 1H NMR internal standard to 
quantify the extent of DEX interaction with K1. DEX 
(5.11 mg, Sigma, D4902) was then added resulting in a 
solution composed of DEX:K1 at a molar ratio of 5:3. The 
solution was aged for 2 days prior to 1H NMR and DOSY 
NMR investigations. Proton NMR spectra and DOSY were 
recorded on a Varian Direct Drive VNMRS 600 spectrom-
eter (Agilent Technologies, Santa Clara CA) operating at a 
magnetic field strength of 14.1 T (600 MHz 1H frequency). 
A dual broadband probe was used. 1H NMR spectra were 
acquired at room temperature using a single pulse excitation 
with a 45° flip angle of 3.6 µ seconds and an acquisition 
time of 1.7 seconds. The repetition time was 1.0 seconds. It 
should be noted that as DEX interacts with the RNTs, the 
corresponding proton integration and diffusion coefficient 
decrease proportionally as a result of the large relaxation 
time of the self-assembled RNTs.
Atomic force microscopy (AFM)
AFM experiments were carried out on a Digital Instruments/
Veeco Instruments MultiMode Nanoscope IV AFM (Plain-
view, NY) equipped with an E scanner. Silicon cantilevers 
(MikroMasch USA, Inc., San Jose, CA) with low spring 
constants of 4.5 N/m were used in tapping mode with a scan 
rate of 0.5–1 Hz and amplitude setpoint of 1 V . K1 (20 µL 
of a 50–250 µg/mL solution) with/without DEX were spin-
coated on freshly cleaved mica at 2,000 rpm for 20 seconds 
and dried in air prior to imaging.
UV-Vis spectroscopy
For UV-Vis experiments (Agilent 8453, Agilent Technologies, 
Santa Clara, CA), the DEX:K1 (5:3 molar ratio) stock solu-
tion containing 4.07 mg of the drug-loaded RNTs in methanol 
(see above) was diluted to 25 µg/mL with methanol. Solutions 
of DEX (5 µg/mL) and K1 (25 µg/mL) in methanol were 
prepared, as well as the same three solutions in dH2O.
DeX loading and release studies
Glass coverslips (Fisher Scientific, Waltham, MA:   circular; 
diameter, 18 mm; thickness, 1 mm) were cleaned with 
methanol, acetone and water in a sonicator. Three groups 
were prepared in dH2O: a) glass coverslips were dipped in a 
water-soluble DEX solution (1 mg/mL, Sigma, St Louis, MO, 
D2915); b) glass coverslips were first soaked in a K1 solution 
(100 µg/mL) and after air-drying, they were then immersed 
into the water-soluble DEX solution (1 mg/mL); and c) 
glass slides were dipped in a K1 solution (100 µg/mL) with 
1 mg/mL water-soluble DEX. Then, all three groups were 
  air-dried and incubated at 37°C in a PBS buffer (3 mL). 
Aliquots were then taken from the supernatant on a daily 
basis over a period of 9 days. The DEX solution was mixed 
with cupric ions in a pH 11 buffer. Because of the reduc-
tion of cupric ions, a cuprous cation was produced and 
spectrophotometrically detected by incorporating with 2-(4-
carboxyquinolin-2-yl) quinoline-4-carboxylic acid (Pierce 
Biotechnology, Rockford, IL). DEX concentrations were 
quantified by comparing with the standard curve. The accu-
mulated DEX release curve was presented as the result.
Contact angle measurements
To confirm the adsorption of K1 on the glass slides, the contact 
angles of 100 µL water droplets were measured before and 
after coating with a K1 solution (100 µg/mL) using a static 
contact angle meter (KRÜSS, FM40, Hamburg, Germany). 
An accurate auto pipette was used to ensure that the volume 
of the sample (20 µL) remained constant across glass slides. 
The contact angles were measured approximately 30 seconds 
after the droplets were placed on the surfaces.
Bioactivity
Osteoblasts (bone-forming cells, ATCC, CRL-11372 popu-
lation numbers ,9) were seeded at 1,000 cells/cm2 in well 
plates and were cultured in Dulbecco’s modified Eagle 
medium (DMEM) medium (Gibco/BRL, Grand Island, NY) 
supplemented with 10% fetal bovine serum (FBS; HyClone, 
Logan, UT) and 1% penicillin/streptomycin (P/S; Hyclone, 
Logan, UT) under standard cell culture conditions (37°C, 
humidified, 5% CO2/95% air environment). DEX-containing 
samples (10 µL) (see controlled release experiments) and 
freshly prepared and sterilized DEX (10−8 M) were added 
to the wells along with the cell culture medium. After the 
prescribed time period, non-adherent cells were removed 
by washing twice with phosphate buffered saline (PBS). 
At the end of 1, 3 and 5 days, osteoblasts were fixed with 
10% normal buffered formalin (NBF; Fisher Scientific, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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Waltham, MA), stained with 4,6-diamidino-2-phenylindole, 
  dihydrochloride (DAPI; Invitrogen, Carlsbad, CA), and 
counted at five random fields of view for each well under a 
fluorescence microscope (Zeiss Axiovert 200M, Peabody).
statistical analysis
Data were expressed using the standard error of the mean 
(SEM). Statistics were performed using a Student’s one-tailed 
t-test, with P , 0.05 considered statistically significant.
Results
Characterization of Drug-loaded rNT-K1
NMR and DOSY were used to characterize the incorporation 
between K1 and DEX. Due to their large molecular weight 
and long relaxation time, K1 and K1-encapsulated DEX 
were not detectable by  1H NMR spectroscopy. Therefore, 
the percentage of drug loading could only be inferred from 
differences in peak heights of the drug relative to an inter-
nal standard (t-BuOH). As shown in Table 1, at the DEX: 
K–G∧C molar ratio of 5:3, approximately 32% of DEX was 
captured by K1. In agreement with this result, a significant 
change in the diffusion coefficient of DEX was observed in 
the DOSY spectra (Table 2).
Tapping mode atomic force microscopy (AFM) showed 
significantly different height profiles for K1 before and after 
incorporation of DEX (Figure 2). In addition, the UV-Vis 
  spectra recorded in methanol showed a significant hypo-
chromic effect at 280 nm and a hyperchromic effect around 
240 nm. In water, on the other hand, a dramatic hyperchromic 
effect was observed around 280 and 240 nm suggesting 
that DEX significantly altered the stacking interaction in 
K1 (Figure 3).
Drug loading and release experiments
For drug loading experiments, K1 samples with/without 
incorporation of DEX were prepared on glass slides. To con-
firm that K1 adhered to the glass slide surfaces, contact angle 
measurements were carried out. A notable decrease in contact 
Table 1 1h NMr spectroscopy of DeX and rNT-encapsulated DeX
DEX peaks 1 2 3 4 5 6
Chemical shift (ppm) 7.39 6.28 6.07 4.59 4.24 3.08
1h integration of DeX before encapsulation 1.43 1.29 1.30 1.45 2.89 1.47
1h integration of DeX after encapsulation 0.98 0.92 0.95 0.97 1.95 0.96
% Change 32 29 27 33 33 35
Notes: The internal standard (t-BuOh) has a chemical shift of 1.22 ppm and an integration corresponding to 9 protons both before and after encapsulation of DeX. see 
supporting information section for NMr spectra.
Abbreviations: DeX, dexamethasone; NMr, nuclear magnetic resonance; rNT, rosette nanotubes.
Table 2 DOsY NMr of DeX only and rNT-encapsulated DeX
DEX peaks 1 2 3 4 5 6 Average
Chemical shift (ppm) 7.39 6.28 6.07 4.59 4.24 3.08 –
Diffusion Coefficient  
(m2/s) of DeX before  
encapsulation
5.6 5.8 5.8 5.8 6 5.8 5.8
Diffusion Coefficient  
(m2/s) of DeX after  
encapsulation
5 5 5 5.2 5.4 5 5.1
Notes: The internal standard (t-BuOh) has a chemical shift of 1.22 ppm and an 
integration of corresponding to 9 protons both before and after encapsulation of 
DeX. see supporting information section for NMr spectra.
Abbreviations: DeX, dexamethasone; NMr, nuclear magnetic resonance; rNT, 
rosette  nanotubes;  DOsY  NMr,  diffusion  ordered  nuclear  magnetic  resonance 
spectroscopy.
angles (from 54.1 ± 2.1 to 43.9 ± 3.5) for the K1-coated slides 
was measured confirming that the hydrophilicity of the glass 
slide surface increased upon K1 adsorption.
To further test drug loading ability and release kinetics 
of K1, a release experiment was conducted in a physi-
ological environment: specifically, in water buffer and at 
37oC incubation. Two approaches were used to incorporate 
DEX with K1. The first approach consisted of physically 
adsorbing K1 onto a glass slide and then dipping the slide 
in a water-soluble DEX solution. The second approach 
consisted of assembling K1 in the water-soluble DEX 
solution and then adsorbing the complex on a glass slide. 
Results showed that K1 in the first approach retained 
approximately 24.8% more DEX than the control sample 
(uncoated glass slide dipped in water-soluble DEX solu-
tion) and released DEX up to 6 days. Using the second 
approach, K1 incorporated approximately 42% more DEX 
than the control sample (Figure 4).
Drug bioactivity tests
After establishing the ability of K1 to incorporate and slowly 
release drugs, one important concern is whether the released 
drugs are still bioactive. To test the bioactivity of the drug, 
commercially available fresh DEX, along with released 
DEX from glass slides and from K1 were used as additives 
separately for osteoblast culture. As shown in Figure 5, International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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Figure 3 Comparison of UV-Vis absorbance curves in methanol (Left) and water (right). A) 0.005 mg/mL DeX, B) 0.025 mg/mL DeX-rNTs and C) 0.025 mg/mL rNTs.
There is no UV absorbance curve of DeX only in water, because DeX precipitates in water.
Abbreviations: rNT, rosette nanotubes; DeX, dexamethasone.
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Figure 2 Tapping mode AFM height profiles of (A) rNTs and (B) rNT-encapsulated DeX. Average heights measured for rNTs and rNT-DeX complexes were 2.91 ± 0.95 nm 
and 7.04 ± 0.33 nm, respectively. 
Abbreviations: AFM, Atomic force microscopy; rNT, rosette nanotubes; DeX, dexamethasone.
osteoblast densities from the three groups with DEX were 
higher relative to the negative controls (without DEX). 
Importantly, DEX released from K1 increased osteoblast 
density the most.
Discussion
Traditional drug delivery systems involve chemical or 
physical modification to bind with specific drugs for their 
controlled release. Chemical modification aims to establish 
chemical bonds (such as covalent bonds) between the drug 
and the carriers. Physical adsorption employs simple pro-
cedures, but gives low drug loading and fast release under 
physiological conditions, thus resulting in limited cell-drug 
interactions.24,25 However, RNTs have unique design   features 
that make them attractive for drug delivery purposes. Their 
hydrophobic core resulting from base stacking and self-
assembly attracts and entraps small hydrophobic molecules 
behind a hydrophilic and biocompatible outer surface. 
Entrapped, water insoluble drugs can thus be delivered under 
physiological conditions to bone cells.11,12
In this study, DEX was chosen as a model drug because 
of its wide use in orthopedic applications since it is an anti-
inflammatory agent and can control stem cell differentia-
tion into osteoblasts.26,27 DOSY NMR and AFM suggested 
the incorporation of DEX in K1. Moreover, since UV-Vis 
spectroscopy showed a significant hyperchromic effect upon 
DEX encapsulation by K1 in water, any change in K1’s 
UV-Vis spectrum may be associated with the formation of a International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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stable DEX-K1 complex, possibly via intercalation/stacking 
interactions.
To further understand how DEX is incorporated into K1 
and to determine the DEX loading and release behavior, 
the DEX-K1 complex was prepared using two different 
  methods: 1) adsorbing DEX onto K1 coated glass slides; and 
2) assembling K1 with DEX solution. Results showed that 
the second method led to a larger amount of DEX loading, 
and a prolonged release under physiological conditions (37°C 
in aqueous buffer). These results support the idea that DEX 
is entrapped inside the hydrophobic core of K1.
Equally important is the biological activity of the 
released DEX. Since DEX has been reported to increase 
cell density,22,28 we investigated osteoblast cell cultures 
with no additives (negative controls), commercially avail-
able water-soluble DEX (positive controls), released DEX 
from uncoated glass slides, and released DEX from the 
DEX-K1-coated glass slides. Higher osteoblast densities 
from the three groups with DEX were observed compared 
to the negative control (without DEX). In addition, DEX-
K1-coated glass slides not only exerted the same biological 
effect as the drug released from DEX-coated glass slides, but 
also promoted higher osteoblast density, in agreement with 
earlier reports.11,12,17,18,29
In summary, these results suggest that DEX was incorpo-
rated into K1 in the process of self-assembly by hydrophobic 
and base stacking interactions. Thus, for orthopedic applica-
tions, RNTs not only enhance osteoblast adhesion and sub-
sequent functions (such as calcium deposition) as previously 
shown,11,12,20 but they can also incorporate water-insoluble 
drugs (such as DEX) and release them in physiological media 
over an extended period of time.
Conclusions
We have demonstrated that RNTs have unique chemical and 
physical properties that make them particularly attractive 
for drug delivery applications. For instance, they can be 
modified: a) chemically with various peptides to tailor them 
for specific tissue-engineering applications; b) physically, 
by drug-entrapment within their core; and c) structurally, by 
synthetically altering their dimensions (length, diameter) to 
accommodate a broad range of therapeutic modalities.
The incorporation of DEX into K1 was established by 
1H-NMR spectroscopy, DOSY NMR, UV-Vis spectroscopy, 
AFM, and in vitro osteoblast cultures. This study demon-
strated that K1, a member of the RNT family, can encapsulate 
DEX via a simple self-assembly process, and release it under 
physiological conditions, over an extended period of time 
spanning 9 days. The released drug enhanced the established 
biological activity of K1. We envision, as a result, several 
applications in drug delivery for the RNT platform.
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Figure S1 1h spectrum of DeX control (before incorporating with rNTs).
Abbreviations: rNT, rosette nanotubes; DeX, dexamethasone.
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Figure S2 1h spectrum of DeX/rNT composites (after incorporating with rNTs).
Abbreviations: rNT, rosette nanotubes; DeX, dexamethasone.
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Figure S3 DOsY of DeX (before incorporating with rNTs).
Abbreviations: rNT, rosette nanotubes; DeX, dexamethasone; DOsY, diffusion ordered nuclear magnetic resonance spectroscopy.
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Figure S4 DOsY of DeX/rNT (after incorporating with rNTs).
Abbreviations: rNT, rosette nanotubes; DeX, dexamethasone; DOsY, diffusion ordered nuclear magnetic resonance spectroscopy.